Merck ($MRK) removes 'fast-acting relief' from allergy ads

After competitor complaints and U.K. regulatory action, Merck ($MRK) will remove its "fast-acting relief" claims from its Clarityn--sold in the U.S. as Claritin--allergy pills. Johnson & Johnson complained to the U.K. Medicines and Healthcare products Regulatory Agency about Merck's claims that its pill provided fast-acting relief from hay fever symptoms, saying there wasn't enough evidence to back the statement. In November, the agency sided with J&J, saying the fast-acting moniker should only be used when relief occurs within 30 minutes, which Merck could not definitively prove.

The MHRA also said that any product using Clarityn's active ingredient, loratadine, should remove similar claims.

- read the Dow Jones piece

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.